Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.76 +0.13 (+0.89%)
Streaming Delayed Price Updated: 12:54 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: Reuters
According to a source with the Drug Controller General of India, Merck & Co Inc's (NYSE: MRK) antiviral drug molnupiravir has not shown "significant... 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) 
Via Benzinga
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-... 
Via Benzinga
Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Mu - The Newest Worry
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Delta Outbreak
The US market was droopy because of poor private sector jobless numbers. 
Via Talk Markets
BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range
BioDelivery Sciences International Inc (NASDAQ: BDSI) has reported Q2 sales of $41.4 million, + 13.3% Y/Y, missing the consensus of $42.4 million. Sales growth... 
Via Benzinga
Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL
From Dr. Reddy’s Laboratories Limited
Via Business Wire
Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
DrReddy's Laboratories Ltd (RDY) Q1 2022 Earnings Call Transcript
RDY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Full News Day
The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier. 
Via Talk Markets
Topics Energy
Banned Merger
Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2... 
Via Benzinga
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Delta Defeats Bulls
Stocks tended to crash without rhyme or reason. 
Via Talk Markets
Fireworks Display
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked. 
Via Talk Markets
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs. Interesting Facts: The largest company by market cap to set a new 52-week high was Microsoft (NASDAQ:... 
Via Benzinga
New Month And Half Year
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F
From Dr. Reddy’s Laboratories Limited
Via Business Wire
Stocks That Hit 52-Week Highs On Thursday
This morning 158 companies set new 52-week highs. Intriguing Points: NVIDIA (NASDAQ:NVDA) was the largest firm on a market cap basis to set a new 52-week high. The... 
Via Benzinga
Moderna Stock Surges To Record High As Covid Battle Rages In India
Moderna stock surged to a record high Tuesday after its Covid vaccine protected against a handful of variants in an early-phase study. 
Via Investor's Business Daily
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.